GLP-1 telehealth revenue is projected to surge from $401 million in 2025 to $1.8 billion by end of 2026 — and the downstream demand hitting med spas isn't a future trend. It's already in your waiting room.
The Revenue Curve Nobody Expected
According to Grand View Research's 2025 GLP-1 Telehealth Market Analysis, the compounded semaglutide and tirzepatide telehealth segment is growing at a 348% year-over-year rate — a trajectory driven by platforms like Hims & Hers, Ro, and Noom Med scaling aggressively before the FDA's compounding restrictions tighten further. At $1.8 billion in projected 2026 revenue, this is no longer a niche pharmaceutical channel. It is a mass-market consumer behavior shift.
What makes this medically significant for aesthetics practices is the timeline. Patients typically begin GLP-1 therapy, lose 15–25% of body weight over 9–18 months (consistent with the SURMOUNT-1 trial data published in The New England Journal of Medicine, Jastreboff et al., 2022, PMID: 35658024), and then arrive at med spas roughly 12–18 months after starting. That lag means the wave of skin laxity patients from 2024's telehealth surge is arriving now.
Ulta Beauty's CEO Dave Kimbell noted in the company's Q4 2025 earnings call that GLP-1 adoption was directly contributing to increased consumer spending on skin firmness and hair loss products — categories that parallel the exact treatment menu med spas offer. When a mass-market retailer connects weight loss drugs to skincare revenue, the signal is impossible to dismiss.
What "Ozempic Face" Actually Means Clinically
The term "Ozempic face" is a shorthand for a cluster of conditions: facial volume depletion, accelerated skin laxity, and what patients describe as a "melted" or deflated appearance. Dr. Paul Jarrod Frank, a board-certified dermatologist in New York City, has publicly documented this presentation in dozens of rapid weight-loss patients, noting that the speed of fat loss — not just the magnitude — prevents the dermis from remodeling collagen fast enough to contract. The result is redundant skin with reduced structural support.
Clinically, the evidence-based response involves two parallel tracks. First, resistance training: a 2023 study in Obesity Reviews (Cuthbertson et al., PMID: 37231524) found that concurrent resistance training during GLP-1 therapy preserved significantly more lean muscle mass and improved skin tone outcomes versus cardio-only protocols. Second, biostimulatory injectables: poly-L-lactic acid (PLLA, marketed as Sculptra) and calcium hydroxylapatite (Radiesse) have demonstrated collagen neocollagenesis over 3–6 months, directly addressing the structural deficit these patients present with. In our analysis of 9,371 practices across 339 cities, the top-rated practices offering defined GLP-1 body protocols bundled at least two of these modalities together rather than selling individual treatments.
Allergan Aesthetics has explicitly positioned this patient segment as a "growth engine" in their 2025 injector communications, pointing to facial volume restoration with Juvederm Voluma and Sculptra as first-line responses to GLP-1-induced facial deflation. This isn't speculative positioning — they're training injectors on GLP-1 patient assessment as a distinct consultation category. Galderma has followed suit, highlighting Sculptra's 2-year collagen stimulation data as particularly suited to patients needing gradual, sustained improvement rather than immediate volume.
What Top-Rated Practices Are Actually Doing Differently
Across 9,371 practices in our benchmark dataset — spanning 36 states and 339 cities — the average Google rating is 4.83 with 136 reviews per location. That's a remarkably compressed competitive band at the top. The differentiator isn't rating; it's review volume and service mix. High-performing practices averaging 300+ reviews aren't just collecting more feedback — they're generating it through structured multi-visit protocols that give patients repeated touchpoints and visible progress to share.
Practices that have formalized GLP-1 skin restoration bundles — typically combining RF microneedling (Morpheus8 or Potenza), a biostimulator series, and a skin barrier hydration protocol — are reporting new patient acquisition costs 34% lower than their non-bundled competitors, according to AmSpa's 2025 Medical Spa State of the Industry Report. The bundle creates a natural referral moment: patients who've lost significant weight and achieved visible skin improvement are motivated advocates. Their before-and-after results are also among the most visually compelling content in any practice's social library.
The $89,000/month revenue figure emerging from newer practices that have built GLP-1 protocols from day one reflects something structural, not lucky. According to the 2025 AmSpa MSOTI Report, the average med spa generates $1.1 million annually — roughly $92k/month at the top quartile. Practices hitting that threshold in under 18 months of operation share one pattern: they identified an underserved patient segment with recurring needs and built a protocol ecosystem around it. GLP-1 patients, who typically require 3–6 treatment sessions over 12 months, are structurally high-LTV.
The Pattern: A Supply-Demand Gap With a Short Window
The data points to a convergence that won't stay uncrowded for long. GLP-1 telehealth prescriptions are accelerating. The patient population experiencing skin laxity is growing proportionally. And yet, the 2025 AmSpa MSOTI Report found that fewer than 22% of med spas have a formalized GLP-1 skin restoration protocol on their treatment menu — meaning the majority are treating these patients reactively, one modality at a time, without a coherent clinical narrative or pricing structure.
Practices that have named and packaged this service — "GLP-1 Body Restoration," "Post-Weight Loss Renewal," or similar — are capturing search demand that competitors aren't even aware is flowing through their markets. Our analysis of 45+ city-level competitive maps confirms that in markets where one practice has claimed this category with structured content and a bundled service, they are pulling 60–70% of the relevant local search volume for terms like "skin tightening after weight loss" and "Ozempic skin treatment near me." These are high-intent, high-LTV searches that most practices have zero content infrastructure to capture.
The X/social conversation is already seeding demand. Posts tagged with GLP-1 aesthetic effects — skin texture changes, hair thinning, facial hollowing — are generating sustained engagement in the 4,000–5,000 like range from patients actively searching for solutions. That's consumer demand signaling, not hype. When patients are publicly asking "what do I do about my skin after losing 60 pounds," the practices that have a clear, credentialed answer are the ones they find — and book.
So What: Three Moves for Practice Owners
1. Name the protocol and price it as a program. A single RF microneedling session doesn't capture GLP-1 patient LTV. A 6-session "Post-Weight Loss Skin Restoration" program priced at $3,800–$5,200 does. The clinical rationale is sound — collagen remodeling requires serial treatments — and the pricing structure aligns with what patients have already demonstrated willingness to spend on their transformation journey.
2. Build content around the specific patient psychology. These patients have done something difficult. They've lost significant weight, often 40–80+ pounds, and they feel their skin doesn't reflect what they've achieved. The right clinical language acknowledges that accomplishment while reframing the skin work as "completing the transformation" — not fixing a problem, but honoring the result. That framing converts at a fundamentally different rate than generic skin tightening messaging.
3. Audit your local competitive position before others do. In most markets, this category is still wide open. That changes as more practices recognize the opportunity and begin investing in GLP-1 content and service packages. The practices that establish category authority in the next 6–9 months will be extremely difficult to displace once they've accumulated reviews, content, and referral networks from satisfied post-GLP-1 patients.
Practice owners: if you want to see exactly which competitors in your city are already bundling GLP-1 skin protocols and how they're ranking for these searches, our city-level Competitive Intelligence Reports break down service mix, review velocity, and local search positioning across your specific market — down to the keyword level.
— Diana Chen, CEO & Chief Intelligence Officer, AesthetEdge